The Role of Metabolic Reprogramming in Kidney Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Jun 17

PMID 38884097

Authors

Ziyi Chen

Xiaohong Zhang

Affiliations

Soon will be listed here.

Abstract

Metabolic reprogramming is a cellular process in which cells modify their metabolic patterns to meet energy requirements, promote proliferation, and enhance resistance to external stressors. This process also introduces new functionalities to the cells. The 'Warburg effect' is a well-studied example of metabolic reprogramming observed during tumorigenesis. Recent studies have shown that kidney cells undergo various forms of metabolic reprogramming following injury. Moreover, metabolic reprogramming plays a crucial role in the progression, prognosis, and treatment of kidney cancer. This review offers a comprehensive examination of renal cancer, metabolic reprogramming, and its implications in kidney cancer. It also discusses recent advancements in the diagnosis and treatment of renal cancer.

References

Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J . Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. Eur Urol. 2018; 75(5):752-763. DOI: 10.1016/j.eururo.2018.09.030. View

Zhu H, Wang X, Lu S, Ou K . Metabolic reprogramming of clear cell renal cell carcinoma. Front Endocrinol (Lausanne). 2023; 14:1195500. PMC: 10280292. DOI: 10.3389/fendo.2023.1195500. View

Cai X, Wang X, Li J, Dong J, Liu J, Li N . High expression of CD39 in gastric cancer reduces patient outcome following radical resection. Oncol Lett. 2016; 12(5):4080-4086. PMC: 5104239. DOI: 10.3892/ol.2016.5189. View

LaGory E, Wu C, Taniguchi C, Ding C, Chi J, von Eyben R . Suppression of PGC-1α Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma. Cell Rep. 2015; 12(1):116-127. PMC: 4518559. DOI: 10.1016/j.celrep.2015.06.006. View

Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T . Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013; 45(8):860-7. DOI: 10.1038/ng.2699. View

Yu H, Kielczewska A, Rozek A, Takenaka S, Li Y, Thorson L . Sequestosome-1/p62 is the key intracellular target of innate defense regulator peptide. J Biol Chem. 2009; 284(52):36007-36011. PMC: 2794716. DOI: 10.1074/jbc.C109.073627. View

Kaelin Jr W . Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002; 2(9):673-82. DOI: 10.1038/nrc885. View

Doherty J, Cleveland J . Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013; 123(9):3685-92. PMC: 3754272. DOI: 10.1172/JCI69741. View

Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

10.

Li X, Wenes M, Romero P, Huang S, Fendt S, Ho P . Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019; 16(7):425-441. DOI: 10.1038/s41571-019-0203-7. View

11.

Qiu B, Ackerman D, Sanchez D, Li B, Ochocki J, Grazioli A . HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2015; 5(6):652-67. PMC: 4456212. DOI: 10.1158/2159-8290.CD-14-1507. View

12.

Carvalho-Santos Z, Cardoso-Figueiredo R, Elias A, Tastekin I, Baltazar C, Ribeiro C . Cellular metabolic reprogramming controls sugar appetite in Drosophila. Nat Metab. 2020; 2(9):958-973. DOI: 10.1038/s42255-020-0266-x. View

13.

Abdel-Wahab A, Mahmoud W, Al-Harizy R . Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019; 150:104511. DOI: 10.1016/j.phrs.2019.104511. View

14.

Wettersten H, Abu Aboud O, Lara Jr P, Weiss R . Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017; 13(7):410-419. DOI: 10.1038/nrneph.2017.59. View

15.

Hakimi A, Reznik E, Lee C, Creighton C, Brannon A, Luna A . An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell. 2016; 29(1):104-116. PMC: 4809063. DOI: 10.1016/j.ccell.2015.12.004. View

16.

Kondo K, Kim W, Lechpammer M, Kaelin Jr W . Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003; 1(3):E83. PMC: 300692. DOI: 10.1371/journal.pbio.0000083. View

17.

Shroff E, Eberlin L, Dang V, Gouw A, Gabay M, Adam S . MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc Natl Acad Sci U S A. 2015; 112(21):6539-44. PMC: 4450371. DOI: 10.1073/pnas.1507228112. View

18.

Li Y, Sha Z, Peng H . Metabolic Reprogramming in Kidney Diseases: Evidence and Therapeutic Opportunities. Int J Nephrol. 2021; 2021:5497346. PMC: 8560294. DOI: 10.1155/2021/5497346. View

19.

Hsieh J, Le V, Oyama T, Ricketts C, Ho T, Cheng E . Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2018; :JCO2018792549. PMC: 6299341. DOI: 10.1200/JCO.2018.79.2549. View

20.

Mannava S, Grachtchouk V, Wheeler L, Im M, Zhuang D, Slavina E . Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle. 2008; 7(15):2392-400. PMC: 3744895. DOI: 10.4161/cc.6390. View